Answers are grounded in this paper and cite their sources.
We examined the effect of an inhibitor of secretory phospholipase A2 type II (LY311727) and of a specific inhibitor of serine proteases (AEBSF) in a murine model of acute toxoplasmosis. LY311727 did not afford any significant protection and produced earlier mortality compared with untreated mice at a dose of 100 mg/kg. In contrast, AEBSF demonstrated a significant increase in length of survival, and this effect was enhanced when AEBSF was administered with non-protective doses of pyrimethamine.
No takes yet. Share an insight, caveat, or question.
Rafael Buitrago-Rey (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: